US stocks move: Eli Lilly surges over 6% to a record high as leukemia drug Jaypirca receives positive recommendation from the European Union’s CHMP

Golden Globe June 26｜A certain exchange surged by more than 6%, reaching $1,200.55, marking a record high. In terms of news, the company announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of its non-covalent Bruton’s tyrosine kinase (BTK) inhibitor Jaypirca, for the treatment of adult chronic lymphocytic leukemia (CLL) patients who have received or not received BTK inhibitor therapy. This recommendation covers the entire line of treatment for this indication.